HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT)

HC Wainwright restated their neutral rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report sent to investors on Wednesday morning,Benzinga reports.

Separately, StockNews.com cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th.

Galectin Therapeutics Trading Up 4.8 %

Galectin Therapeutics stock opened at $1.32 on Wednesday. The company has a market capitalization of $82.85 million, a P/E ratio of -1.81 and a beta of 0.69. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $4.27. The firm’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.95.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, equities research analysts predict that Galectin Therapeutics will post -0.73 earnings per share for the current year.

Institutional Investors Weigh In On Galectin Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its stake in Galectin Therapeutics by 9.3% during the 3rd quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after purchasing an additional 21,399 shares during the period. Kovitz Investment Group Partners LLC bought a new stake in shares of Galectin Therapeutics in the third quarter valued at approximately $117,000. Barclays PLC grew its stake in shares of Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after acquiring an additional 21,598 shares during the last quarter. Geode Capital Management LLC increased its position in Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock worth $2,372,000 after acquiring an additional 20,817 shares during the period. Finally, Soltis Investment Advisors LLC acquired a new position in Galectin Therapeutics during the 3rd quarter valued at $387,000. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.